INDV Indivior Pharmaceuticals, Inc.
FY2025 10-K
Indivior Pharmaceuticals, Inc. (INDV) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: specialty pharmaceuticals focused on addiction treatment and opioid dependence therapies
- • Emphasis on SUBLOCADE growth driving expected decline in U.S. revenue share from international markets this year
Management Discussion & Analysis
- • Revenue increased by $87M in 2025 vs $28M in 2024 from prior year performance obligations adjustments
- • No profitability or operating margin figures disclosed in the text
Risk Factors
- • FDA-required 2022 label change on SUBOXONE Film due to dental injury risk triggering ongoing product liability lawsuits
- • Exposure to U.K. Financial Services and Markets Act 2000 claims over alleged misleading disclosure about SUBOXONE product-hopping scheme
Financial SummaryXBRL
Revenue
$1.2B
Net Income
$210M
Gross Margin
80.2%
Operating Margin
21.1%
Net Margin
16.9%
ROE
-214.3%
Total Assets
$1.2B
EPS (Diluted)
$1.64
Operating Cash Flow
-$27M
Source: XBRL data from Indivior Pharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Indivior Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.